Materiały źródłowe

• #1 How we diagnose Myelodysplastic syndromes

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11427428/

  The Myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by ineffective hematopoiesis that results in dysplasia in hematopoietic cells and peripheral cytopenias, especially anemia, and a propensity to leukemic transformation. […] The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings, but the gold standard for MDS diagnosis is still BM examination with the presence of uni-or multi-lineage dysplasia and increased blast percentage, together with exclusion of other reasons. […] Cytogenetics is also an essential part of the diagnostic and prognostic processes. […] Unfortunately, since we are dealing with a heterogenous group of disorders, in contrast with many other diseases, there is no single specific diagnostic test or definitive diagnostic criteria for MDS.

• #2

  https://haematologica.org/article/view/haematol.2023.284937

  The myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by BM dysplasia, macrocytic anemia or cytopenia with a tendency for leukemic transformation. […] The gold standard for the diagnosis of MDS is still BM examination with the presence of uni-or multi-lineage dysplasia and blast percentage, together with exclusion of other reasons. […] Cytogenetics is also a part of the diagnostic process. […] This review summarizes the current steps in the diagnostic approach for a patient suspected of having MDS. […] The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings. […] MDS is suspected when there are appropriate clinical and laboratory findings, especially in the elderly.

• #3 Diagnosis of Myelodysplastic Syndrome (MDS) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome/diagnosis

  Myelodysplastic syndrome (MDS) can be difficult to diagnose. […] Many people who are diagnosed with MDS go to their doctor with some or all of the symptoms typical of MDS. Other people are diagnosed with MDS even though they dont have any symptoms. […] Proper diagnosis is crucial so that you receive the most-effective treatment for MDS. Often, you will be referred to a hematologist (a doctor who specializes in blood disorders). A definitive diagnosis can be provided only after a specialist called a hematopathologist examines a sample of your bone marrow. […] Abnormalities in this test provide the first sign of the disease. In MDS, red blood cell levels may be low, which causes anemia. […] If blood tests do not show another reason for the abnormal blood counts, samples of your bone marrow will be examined to look for MDS.

• #4 Myelodysplastic Syndrome (MDS): Symptoms, Types, Treatment

  https://www.healthline.com/health/cancer/mds-hematology

  Myelodysplastic syndromes (MDS) are cancers that affect blood cells in the bone marrow. […] Keep reading to learn more about MDS, symptoms to look out for, and how its diagnosed and treated. […] MDS can be difficult to diagnose because they can be hard to distinguish from other conditions that affect the blood and bone marrow. […] After getting your medical history and doing a physical examination, a doctor will use the following tests to help diagnose MDS: complete blood count (CBC) with differential to measure the amounts of different blood cell types, peripheral blood smear to assess the appearance of blood cells under a microscope, tests of iron, vitamin B12, or folate levels to rule out other causes of anemia, bone marrow aspiration and biopsy to provide samples that can be examined to detect abnormalities associated with MDS, chromosome tests called cytogenetics to look for chromosomal changes that appear in MDS, genetic testing to check for certain genetic changes that happen in MDS.

• #5 Diagnosis of Myelodysplastic Syndrome (MDS) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome/diagnosis

  Myelodysplastic syndrome (MDS) can be difficult to diagnose. […] Many people who are diagnosed with MDS go to their doctor with some or all of the symptoms typical of MDS. Other people are diagnosed with MDS even though they dont have any symptoms. […] Proper diagnosis is crucial so that you receive the most-effective treatment for MDS. Often, you will be referred to a hematologist (a doctor who specializes in blood disorders). A definitive diagnosis can be provided only after a specialist called a hematopathologist examines a sample of your bone marrow. […] Abnormalities in this test provide the first sign of the disease. In MDS, red blood cell levels may be low, which causes anemia. […] If blood tests do not show another reason for the abnormal blood counts, samples of your bone marrow will be examined to look for MDS.

• #6 Diagnosis of Myelodysplastic Syndrome (MDS) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/myelodysplastic-syndrome/diagnosis

  Myelodysplastic syndrome (MDS) can be difficult to diagnose. […] Many people who are diagnosed with MDS go to their doctor with some or all of the symptoms typical of MDS. Other people are diagnosed with MDS even though they dont have any symptoms. […] Proper diagnosis is crucial so that you receive the most-effective treatment for MDS. Often, you will be referred to a hematologist (a doctor who specializes in blood disorders). A definitive diagnosis can be provided only after a specialist called a hematopathologist examines a sample of your bone marrow. […] Abnormalities in this test provide the first sign of the disease. In MDS, red blood cell levels may be low, which causes anemia. […] If blood tests do not show another reason for the abnormal blood counts, samples of your bone marrow will be examined to look for MDS.

• #7 Myelodysplastic Syndrome (MDS): Diagnosis & Treatment | NewYork-Presbyterian

  https://www.nyp.org/cancer/blood-cancer/myelodysplastic-syndrome-mds/treatment

  How is MDS Diagnosed? Diagnosis To diagnose myelodysplastic syndrome, your doctor will conduct a physical exam, assess your symptoms, and review your medical history. They may then order specific blood and bone marrow tests. […] Tests to diagnose MDS may include: […] Complete blood count (CBC) with differential. This blood test counts the number of red blood cells and platelets, the number and type of white blood cells, and the amount of hemoglobin in the red blood cells. […] Peripheral blood smear. This blood test will look for changes in the type, number, size, and shape of the blood cells. It can determine if you have too much iron in your red blood cells. […] Cytogenetic analysis. Your blood or bone marrow will be analyzed for changes in the blood cell chromosomes, including missing, broken, rearranged, or extra chromosomespotential signs of genetic disease or some forms of cancer.

• #8 Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds

  Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) […] The epidemiology, clinical manifestations, pathologic features, diagnosis, and classification of MDS are reviewed in this topic. […] Evaluation of a patient suspected to have MDS involves clinical assessment, laboratory studies, and bone marrow examination. […] Diagnosis of MDS requires persistent cytopenias and <20 percent blasts in peripheral blood (PB)/bone marrow (BM) plus either characteristic cytogenetic/molecular features or dysplastic morphology. [...] MDS should be considered in any patient with unexplained cytopenia(s) or clinical findings associated with anemia, infections, or bleeding/bruising; morphologic dysplasia of blood or marrow; or unexplained bone marrow failure. [...] Diagnostic criteria for MDS are: Cytopenia(s) – One or more cytopenias that cannot be explained by a drug, toxin, vitamin deficiency, infection, or other condition: Hemoglobin – <10 g/dL (100 g/L)

• #9 Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds

  Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) […] The epidemiology, clinical manifestations, pathologic features, diagnosis, and classification of MDS are reviewed in this topic. […] Evaluation of a patient suspected to have MDS involves clinical assessment, laboratory studies, and bone marrow examination. […] Diagnosis of MDS requires persistent cytopenias and <20 percent blasts in peripheral blood (PB)/bone marrow (BM) plus either characteristic cytogenetic/molecular features or dysplastic morphology. [...] MDS should be considered in any patient with unexplained cytopenia(s) or clinical findings associated with anemia, infections, or bleeding/bruising; morphologic dysplasia of blood or marrow; or unexplained bone marrow failure. [...] Diagnostic criteria for MDS are: Cytopenia(s) – One or more cytopenias that cannot be explained by a drug, toxin, vitamin deficiency, infection, or other condition: Hemoglobin – <10 g/dL (100 g/L)

• #10 Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds

  Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) […] The epidemiology, clinical manifestations, pathologic features, diagnosis, and classification of MDS are reviewed in this topic. […] Evaluation of a patient suspected to have MDS involves clinical assessment, laboratory studies, and bone marrow examination. […] Diagnosis of MDS requires persistent cytopenias and <20 percent blasts in peripheral blood (PB)/bone marrow (BM) plus either characteristic cytogenetic/molecular features or dysplastic morphology. [...] MDS should be considered in any patient with unexplained cytopenia(s) or clinical findings associated with anemia, infections, or bleeding/bruising; morphologic dysplasia of blood or marrow; or unexplained bone marrow failure. [...] Diagnostic criteria for MDS are: Cytopenia(s) – One or more cytopenias that cannot be explained by a drug, toxin, vitamin deficiency, infection, or other condition: Hemoglobin – <10 g/dL (100 g/L)

• #11 Myelodysplastic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK534126/

  The following criteria are required for diagnosis: One or more peripheral blood cytopenias (anemia, neutropenia, and/or thrombocytopenia) that cannot be explained by other causes, defined as hemoglobin less than 10 g/dL (100 g/L); absolute neutrophil count less than 1.8 x 10/L (less than 1800/microL); platelets less than 100 x 10/L (less than 100,000/microL). […] Blasts account for less than 20% of nucleated cells in the bone marrow and/or peripheral blood. […] Evidence for dysplasia in greater than 10% of cell lines (red cell precursors, granulocytes, or megakaryocytes). […] The mainstay of treatment for MDS involves the assessment of symptoms and potential morbidity attributed to the disease. […] Patients do not always require treatment as long as they are asymptomatic, and most can be treated with supportive measures such as intermittent blood or platelet transfusions.

• #12 Diagnosis and Classification of Myelodysplastic Syndrome | IntechOpen

  https://www.intechopen.com/chapters/64871

  The chosen diagnostic criterion of MDS is the dysplasia in 10% of total count, this morphology features can point to underlying pathological cytogenetic changes which suggestive MDS diagnosis according to the World Health Organization (WHO) 2016 revision. […] The minimal prerequisites diagnostic guidelines for MDS according to an International Working Group (IWG) are: (1) stable cytopenia for 6 months unless accompanied a specific chromosomal analysis (Karyotype) or bilineage dysplasia; (2) the exclusion of other potential disorders as a primary reason for dysplasia or cytopenia or both. […] According to NCCN the diagnosis of MDS requires 1 of MDS-related criteria: (1) dysplasia (10% in 1 of bone marrow cell line); (2) presence of 519% blast cells; and (3) presence of a specific MDS-linked chromosomal abnormalities like del(5q), del(20q), +8, or 7/del(7q).

• #13 Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds

  Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) […] The epidemiology, clinical manifestations, pathologic features, diagnosis, and classification of MDS are reviewed in this topic. […] Evaluation of a patient suspected to have MDS involves clinical assessment, laboratory studies, and bone marrow examination. […] Diagnosis of MDS requires persistent cytopenias and <20 percent blasts in peripheral blood (PB)/bone marrow (BM) plus either characteristic cytogenetic/molecular features or dysplastic morphology. [...] MDS should be considered in any patient with unexplained cytopenia(s) or clinical findings associated with anemia, infections, or bleeding/bruising; morphologic dysplasia of blood or marrow; or unexplained bone marrow failure. [...] Diagnostic criteria for MDS are: Cytopenia(s) – One or more cytopenias that cannot be explained by a drug, toxin, vitamin deficiency, infection, or other condition: Hemoglobin – <10 g/dL (100 g/L)

• #14 Myelodysplastic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK534126/

  The following criteria are required for diagnosis: One or more peripheral blood cytopenias (anemia, neutropenia, and/or thrombocytopenia) that cannot be explained by other causes, defined as hemoglobin less than 10 g/dL (100 g/L); absolute neutrophil count less than 1.8 x 10/L (less than 1800/microL); platelets less than 100 x 10/L (less than 100,000/microL). […] Blasts account for less than 20% of nucleated cells in the bone marrow and/or peripheral blood. […] Evidence for dysplasia in greater than 10% of cell lines (red cell precursors, granulocytes, or megakaryocytes). […] The mainstay of treatment for MDS involves the assessment of symptoms and potential morbidity attributed to the disease. […] Patients do not always require treatment as long as they are asymptomatic, and most can be treated with supportive measures such as intermittent blood or platelet transfusions.

• #15 Diagnosis and Classification of Myelodysplastic Syndrome | IntechOpen

  https://www.intechopen.com/chapters/64871

  The chosen diagnostic criterion of MDS is the dysplasia in 10% of total count, this morphology features can point to underlying pathological cytogenetic changes which suggestive MDS diagnosis according to the World Health Organization (WHO) 2016 revision. […] The minimal prerequisites diagnostic guidelines for MDS according to an International Working Group (IWG) are: (1) stable cytopenia for 6 months unless accompanied a specific chromosomal analysis (Karyotype) or bilineage dysplasia; (2) the exclusion of other potential disorders as a primary reason for dysplasia or cytopenia or both. […] According to NCCN the diagnosis of MDS requires 1 of MDS-related criteria: (1) dysplasia (10% in 1 of bone marrow cell line); (2) presence of 519% blast cells; and (3) presence of a specific MDS-linked chromosomal abnormalities like del(5q), del(20q), +8, or 7/del(7q).

• #16 Myelodysplastic Syndrome (MDS): Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia

  Providers take several steps to diagnose myelodysplastic syndrome: Complete blood count (CBC) with differential: Your provider will draw blood samples to analyze your red and white blood cells, including counting the number of each white blood cell type. Peripheral blood smear: Theyll check your blood sample for changes in the number, type, shape and size of blood cells, and if you have too much iron in your red blood cells. Cytogenetic analysis: A medical pathologist looks for changes in your blood cell chromosomes by viewing a blood sample under a microscope. Bone marrow biopsy: To do this procedure, your provider inserts a hollow needle into your hipbone to remove bone marrow, blood and a small piece of bone for examination under a microscope. […] Providers evaluate or stage the condition based on the risk that the syndrome will become acute myeloid leukemia (AML). They use a risk rating system called the International Prognostic Scoring System.

• #17 Myelodysplastic Syndrome (MDS): Diagnosis & Treatment | NewYork-Presbyterian

  https://www.nyp.org/cancer/blood-cancer/myelodysplastic-syndrome-mds/treatment

  How is MDS Diagnosed? Diagnosis To diagnose myelodysplastic syndrome, your doctor will conduct a physical exam, assess your symptoms, and review your medical history. They may then order specific blood and bone marrow tests. […] Tests to diagnose MDS may include: […] Complete blood count (CBC) with differential. This blood test counts the number of red blood cells and platelets, the number and type of white blood cells, and the amount of hemoglobin in the red blood cells. […] Peripheral blood smear. This blood test will look for changes in the type, number, size, and shape of the blood cells. It can determine if you have too much iron in your red blood cells. […] Cytogenetic analysis. Your blood or bone marrow will be analyzed for changes in the blood cell chromosomes, including missing, broken, rearranged, or extra chromosomespotential signs of genetic disease or some forms of cancer.

• #18 Tests and treatment for myelodysplastic syndrome | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/myelodysplastic-syndromes/treatment

  Your doctor will examine you and ask questions about your medical history and family medical history. […] To diagnose MDS, you have blood tests and bone marrow tests. […] The blood tests show how many normal blood cells and how many abnormal or immature blood cells you have. […] For a bone marrow test, a doctor or specialist nurse removes a sample of bone marrow to examine it closely. […] As well as looking at the bone marrow cells, your doctor tests for abnormalities in your chromosomes. […] Doctors can use blood or bone marrow samples to look for genetic changes. […] You might have other tests done on the bone marrow to look for other gene changes. […] Doctors can look at the results of cytogenetics and NGS tests together. […] You may have other tests if your specialists need more information to confirm your diagnosis.

• #19

  https://haematologica.org/article/view/haematol.2023.284937

  A thorough history can help to rule out conditions such as paroxysmal nocturnal hemoglobinuria, aplastic anemia, and MPN that may mimic MDS clinically. […] Altogether, the combination of symptoms and laboratory findings along with the exclusion of other causes of anemia/cytopenia, raises the suspicion of MDS, but other investigations are required in order to establish the diagnosis of MDS. […] The next step in the workup of an unexplained anemia (or cytopenia) is a BM examination, still the gold standard for the diagnosis of MDS. […] In summary, BM examination, especially the dysplastic features and blast percentage is mandatory for establishing a diagnosis of MDS. […] While in the year 2024, evaluation of BM morphology and specific staining is still the gold standard for MDS diagnosis, there are several limitations to this diagnostic method.

• #20 Myelodysplastic Syndrome (MDS): Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia

  Providers take several steps to diagnose myelodysplastic syndrome: Complete blood count (CBC) with differential: Your provider will draw blood samples to analyze your red and white blood cells, including counting the number of each white blood cell type. Peripheral blood smear: Theyll check your blood sample for changes in the number, type, shape and size of blood cells, and if you have too much iron in your red blood cells. Cytogenetic analysis: A medical pathologist looks for changes in your blood cell chromosomes by viewing a blood sample under a microscope. Bone marrow biopsy: To do this procedure, your provider inserts a hollow needle into your hipbone to remove bone marrow, blood and a small piece of bone for examination under a microscope. […] Providers evaluate or stage the condition based on the risk that the syndrome will become acute myeloid leukemia (AML). They use a risk rating system called the International Prognostic Scoring System.

• #21 Myelodysplastic Syndrome (MDS): Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia

  Providers take several steps to diagnose myelodysplastic syndrome: Complete blood count (CBC) with differential: Your provider will draw blood samples to analyze your red and white blood cells, including counting the number of each white blood cell type. Peripheral blood smear: Theyll check your blood sample for changes in the number, type, shape and size of blood cells, and if you have too much iron in your red blood cells. Cytogenetic analysis: A medical pathologist looks for changes in your blood cell chromosomes by viewing a blood sample under a microscope. Bone marrow biopsy: To do this procedure, your provider inserts a hollow needle into your hipbone to remove bone marrow, blood and a small piece of bone for examination under a microscope. […] Providers evaluate or stage the condition based on the risk that the syndrome will become acute myeloid leukemia (AML). They use a risk rating system called the International Prognostic Scoring System.

• #22 https://www.lls.org/myelodysplastic-syndromes/diagnosis

  https://www.lls.org/myelodysplastic-syndromes/diagnosis

  A peripheral blood smear is a test in which a hematopathologist examines a drop of blood under a microscope to identify unusual changes in the number, size, shape, appearance and maturity of various blood cells. In myelodysplastic syndromes, blood cells have an abnormal shape or size (dysplasia). […] Erythropoietin (EPO) is a substance made in the kidneys. EPO stimulates the bone marrow to produce more red blood cells. Measuring the amount of EPO in the blood can help determine the cause of anemia. […] These tests are used to confirm MDS. They are usually performed at the same time in a doctor’s office or a hospital. After the samples are taken, a pathologist reviews the samples under the microscope to assess the type, size, appearance and maturity of the cells. […] At the laboratory, a hematopathologist examines the blood and bone marrow cells under a microscope to determine their size, shape and type, and to identify other cell features. […] These laboratory tests examine the MDS blast cells from the blood and bone marrow to check for certain genes, proteins or other molecules to provide information about a persons cancer. Each persons cancer has a unique pattern of biomarkers.

• #23 https://www.lls.org/myelodysplastic-syndromes/diagnosis

  https://www.lls.org/myelodysplastic-syndromes/diagnosis

  An accurate diagnosis is one of the most important aspects of a persons care. Obtaining a precise diagnosis will help the doctor […] Since MDS can be a difficult disease to diagnose, you may want to get a second medical opinion by an experienced hematopathologist before you begin treatment. […] The diagnosis of MDS is based on: […] A doctor will order a complete blood count (CBC) with differential to measure the number of red cells, white cells and platelets in your blood. These measurements indicate the degree to which the MDS cells in the marrow are affecting normal blood cell development. […] Reticulocytes are precursor (immature) cells that develop into mature red blood cells. The reticulocyte count measures the number of reticulocytes in the circulating blood. It can show how quickly these cells are being made and released by the bone marrow and whether the bone marrow is functioning properly.

• #24 https://www.lls.org/myelodysplastic-syndromes/diagnosis

  https://www.lls.org/myelodysplastic-syndromes/diagnosis

  A peripheral blood smear is a test in which a hematopathologist examines a drop of blood under a microscope to identify unusual changes in the number, size, shape, appearance and maturity of various blood cells. In myelodysplastic syndromes, blood cells have an abnormal shape or size (dysplasia). […] Erythropoietin (EPO) is a substance made in the kidneys. EPO stimulates the bone marrow to produce more red blood cells. Measuring the amount of EPO in the blood can help determine the cause of anemia. […] These tests are used to confirm MDS. They are usually performed at the same time in a doctor’s office or a hospital. After the samples are taken, a pathologist reviews the samples under the microscope to assess the type, size, appearance and maturity of the cells. […] At the laboratory, a hematopathologist examines the blood and bone marrow cells under a microscope to determine their size, shape and type, and to identify other cell features. […] These laboratory tests examine the MDS blast cells from the blood and bone marrow to check for certain genes, proteins or other molecules to provide information about a persons cancer. Each persons cancer has a unique pattern of biomarkers.

• #25 Myelodysplastic Syndrome (MDS) Guidelines: Guidelines Summary, Diagnosis, Prognostic Scoring Systems

  https://emedicine.medscape.com/article/207347-guidelines

  In 2016, the World Health Organization (WHO) released a revision to its 2008 classification scheme for myelodysplastic syndrome (MDS). The National Comprehensive Cancer Network (NCCN) has included the revised WHO classification system in its 2017 updated guidelines. […] For the workup in patients with suspected MDS (eg, because of cytopenias), the NCCN recommends the following: History and physical examination, Complete blood count (CBC) with differential, Reticulocyte count, Examination of peripheral blood smear, Bone marrow aspiration with iron stain plus biopsy and cytogenetics by standard karyotyping; consider testing for fibrosis, Serum erythropoietin (prior to red blood cell [RBC] transfusion), RBC folate, serum vitamin B12, Serum ferritin, iron, total iron-binding capacity (TIBC), Documentation of transfusion history, Thyroid-stimulating hormone (TSH), Lactate dehydrogenase (LDH), Genetic testing for somatic mutations (ie, acquired mutations) in genes associated with MDS is highly recommended, Recommend additional molecular and genetic testing for hereditary hematologic malignancy predisposition in a subset of patients, particularly in younger patients, HIV testing if clinically indicated, Consider evaluation of copper deficiency in patients with GI malabsorption, severe malnutrition, gastric bypass surgery, or patients on zinc supplementation, Consider distinction from congenital sideroblastic anemia (CSA).

• #26 How is MDS Diagnosed? – HealthTree for Myelodysplastic Syndromes

  https://healthtree.org/mds/community/how-is-mds-diagnosed

  Diagnosing Myelodysplastic Syndrome (MDS) involves a series of tests, including blood tests, bone marrow tests, and imaging tests. Each of these tests provides crucial information that helps doctors confirm an MDS diagnosis and understand the specifics of the disease. […] If blood tests suggest MDS, a bone marrow examination is essential to confirm the diagnosis. […] To confirm an MDS diagnosis, analyzing the bone marrow cells is required, and specially a type of cell called blast, which is an immature abnormal cell characteristic for MDS and AML (acute myeloid leukemia). The blast cell percentage that determines an MDS diagnosis is less than 20% in the bone marrow and less than 20% in the bloodstream. Doctors will diagnose AML if the blast percentage is above 20% in the bone marrow or above 20% in the bloodstream.

• #27

  https://haematologica.org/article/view/haematol.2023.284937

  A thorough history can help to rule out conditions such as paroxysmal nocturnal hemoglobinuria, aplastic anemia, and MPN that may mimic MDS clinically. […] Altogether, the combination of symptoms and laboratory findings along with the exclusion of other causes of anemia/cytopenia, raises the suspicion of MDS, but other investigations are required in order to establish the diagnosis of MDS. […] The next step in the workup of an unexplained anemia (or cytopenia) is a BM examination, still the gold standard for the diagnosis of MDS. […] In summary, BM examination, especially the dysplastic features and blast percentage is mandatory for establishing a diagnosis of MDS. […] While in the year 2024, evaluation of BM morphology and specific staining is still the gold standard for MDS diagnosis, there are several limitations to this diagnostic method.

• #28 Myelodysplastic Syndromes (MDS)

  https://www.parkwaycancercentre.com/in/learn-about-cancer/types-of-cancer/cancer-details/myelodysplastic-syndromes-(mds)

  Myelodysplastic Syndromes (MDS) are diagnosed through a blood test and bone marrow biopsy. […] In the blood test, called a full blood count, a sample of blood will be sent to the laboratory for investigation. People with MDS typically have low counts of red blood cells as well as platelets, while the white blood cells will usually be abnormal. […] If the blood test suggests MDS is likely, a bone marrow biopsy can help to confirm the diagnosis. A bone marrow biopsy involves taking a sample of bone marrow, usually from the hip bone. This is done under local anaesthetic and takes 15 20 minutes. The sample will also be sent for investigation by the laboratory, to examine the cells present and the haemopoiesis (blood forming) activity in the bone marrow. […] Once MDS is confirmed, further testing on the blood and bone marrow may be done to determine the type of MDS.

• #29 MDS Diagnosis | The University of Kansas Cancer Center | Kansas City

  https://www.kucancercenter.org/cancer/cancer-types/myelodysplastic-syndromes/myelodysplastic-syndromes-diagnosis-screening

  Myelodysplastic syndromes (MDS) can be difficult to diagnose. Proper diagnosis is crucial and is most often made by a hematologist with advanced knowledge of myelodysplastic syndromes. […] To diagnose for myelodysplasia, your doctor takes 2 types of bone marrow samples: A bone marrow biopsy removes a small piece of bone along with the marrow inside the bone. A bone marrow aspirate draws out a sample of liquid from the bone marrow space. […] A hematologist will also look at your blood and bone marrow under a microscope to look for abnormal cell shapes and sizes additional indicators of MDS. Blood tests can also check the number of red blood cells, white blood cells and platelets in your blood, and whether the cells have changed in size or shape. […] To determine the type of MDS cancer, your doctor looks at several factors: Blood cell counts, how many blood cells look abnormal in their earliest forming stages within the bone marrow (also known as dysplasia), whether there’s a lower number of mature blood cells than normal (cytopenia), how many early red blood cells have an iron deposit ring around the nucleus (these are called ring sideroblasts), the percentage of very early blood cells (known as blasts) that are present in the bone marrow, certain chromosome changes at the cellular level in the bone marrow, and the risk that MDS could turn into leukemia. […] Classifying myelodysplasia helps doctors give an accurate diagnosis to better plan for your MDS cancer treatment.

• #30 https://www.lls.org/myelodysplastic-syndromes/diagnosis

  https://www.lls.org/myelodysplastic-syndromes/diagnosis

  A peripheral blood smear is a test in which a hematopathologist examines a drop of blood under a microscope to identify unusual changes in the number, size, shape, appearance and maturity of various blood cells. In myelodysplastic syndromes, blood cells have an abnormal shape or size (dysplasia). […] Erythropoietin (EPO) is a substance made in the kidneys. EPO stimulates the bone marrow to produce more red blood cells. Measuring the amount of EPO in the blood can help determine the cause of anemia. […] These tests are used to confirm MDS. They are usually performed at the same time in a doctor’s office or a hospital. After the samples are taken, a pathologist reviews the samples under the microscope to assess the type, size, appearance and maturity of the cells. […] At the laboratory, a hematopathologist examines the blood and bone marrow cells under a microscope to determine their size, shape and type, and to identify other cell features. […] These laboratory tests examine the MDS blast cells from the blood and bone marrow to check for certain genes, proteins or other molecules to provide information about a persons cancer. Each persons cancer has a unique pattern of biomarkers.

• #31 Myelodysplastic Syndromes | Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/myelodysplastic-syndromes

  Myelodysplastic syndromes (MDS) refer to a group of disorders in which the bone marrow stem cells the primitive cells that give rise to all the different types of blood cells are defective, causing an inadequate production of blood cells. […] MDS is generally diagnosed when a patient is evaluated for low blood counts, although in some MDS patients, the white blood count, platelet count, or both may be elevated. The hallmark feature of MDS is a bone marrow aspirate and biopsy that reveals heavy infiltration with abnormal-looking bone marrow cells. (Myelodysplasia means „funny-looking bone marrow.”) A chromosome analysis, called cytogenetics, is performed on the bone marrow sample. […] The only known cure for MDS is allogeneic blood and marrow transplantation (BMT). Due to the older age of MDS patients and the intensity of allogeneic BMT, however, this treatment often isn’t appropriate for MDS patients.

• #32 Myelodysplastic Syndrome (MDS) Guidelines: Guidelines Summary, Diagnosis, Prognostic Scoring Systems

  https://emedicine.medscape.com/article/207347-guidelines

  The NCCN utilizes the WHO classification system for diagnosis and distinguishes subtypes on the basis of blood and bone marrow findings. MDS with single-lineage dysplasia (MDS-SLD) criteria are as follows: Blood: single cytopenia or bicytopenia, Bone marrow: dysplasia in 10% of one cell line, 5% blasts. MDS with ring sideroblasts (MDS-RS) criteria are as follows: Blood: anemia, no blasts, Bone marrow: 15% of erythroid precursors with ring sideroblasts, or 5% blasts ring sideroblasts if SF3B1 mutation is present. MDS with multilineage dysplasia (MDS-MLD) criteria are as follows: Blood: cytopenia(s), 1 109/L monocytes, Bone marrow: dysplasia in 10% of cells in 2 hematopoietic lineages; 15% ring sideroblasts (or 5% ring sideroblasts if SF3B1 mutation present), 5% blasts. MDS with excess blasts-1 (MDS-EB-1) criteria are as follows: Blood: cytopenia(s) 2-4% blasts, 1 109/L monocytes, Bone marrow: unilineage or multilineage dysplasia, no Auer rods, 5-9% blasts. MDS with excess blasts-2 (MDS-EB-2) criteria are as follows: Blood: cytopenia(s), 5-19% blasts, 1 109/L monocytes, Bone marrow: unilineage or multilineage dysplasia, Auer rods, 10-19% blasts. Myelodysplastic syndrome unclassified (MDS-U) criteria are as follows: Blood: cytopenias, 1% blasts on at least 2 occasions, Bone marrow: unilineage dysplasia or no dysplasia but characteristic MDS cytogenetics, 5% blasts. Myelodysplastic syndrome associated with isolated del(5q) criteria are as follows: Blood: anemia, platelet levels normal or increased, Bone marrow: unilineage erythroid dysplasia, isolated del(5q), 5% blasts one other abnormality except -7/del(7q).

• #33 MDS Diagnosis | The University of Kansas Cancer Center | Kansas City

  https://www.kucancercenter.org/cancer/cancer-types/myelodysplastic-syndromes/myelodysplastic-syndromes-diagnosis-screening

  Myelodysplastic syndromes (MDS) can be difficult to diagnose. Proper diagnosis is crucial and is most often made by a hematologist with advanced knowledge of myelodysplastic syndromes. […] To diagnose for myelodysplasia, your doctor takes 2 types of bone marrow samples: A bone marrow biopsy removes a small piece of bone along with the marrow inside the bone. A bone marrow aspirate draws out a sample of liquid from the bone marrow space. […] A hematologist will also look at your blood and bone marrow under a microscope to look for abnormal cell shapes and sizes additional indicators of MDS. Blood tests can also check the number of red blood cells, white blood cells and platelets in your blood, and whether the cells have changed in size or shape. […] To determine the type of MDS cancer, your doctor looks at several factors: Blood cell counts, how many blood cells look abnormal in their earliest forming stages within the bone marrow (also known as dysplasia), whether there’s a lower number of mature blood cells than normal (cytopenia), how many early red blood cells have an iron deposit ring around the nucleus (these are called ring sideroblasts), the percentage of very early blood cells (known as blasts) that are present in the bone marrow, certain chromosome changes at the cellular level in the bone marrow, and the risk that MDS could turn into leukemia. […] Classifying myelodysplasia helps doctors give an accurate diagnosis to better plan for your MDS cancer treatment.

• #34 Tests for myelodysplastic syndromes (MDS) | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/myelodysplastic-syndromes-mds-/tests-diagnosis/

  Doctors use tests to diagnose MDS, to help them decide what type of MDS you have and to plan your treatment. You might also have tests to monitor the MDS. […] If a full blood count shows you might have MDS, your doctor will usually ask you to have a bone marrow biopsy to confirm the diagnosis. […] Your doctor will arrange for your bone marrow sample to be tested for any changes to the chromosomes and genes in your blood cells. This can help to confirm the diagnosis of MDS. […] Sometimes the results of bone marrow tests do not show if someone definitely has MDS. […] After you’ve been diagnosed, you’ll usually have regular blood tests to monitor your MDS. […] MDS usually causes at least one of your blood counts to be lower than normal. […] In some types of MDS, the body makes too many blasts and they dont develop properly into more mature blood cells. These faulty blasts can build up in the bone marrow and blood, meaning theres not as much room for healthy blood cells. […] If the number of blasts increases, this could be a sign that the MDS is progressing. For some people, MDS can turn into a different type of blood cancer called acute myeloid leukaemia. Most doctors agree that MDS has become AML when the percentage of blasts reaches 20%.

• #35 Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes

  Patients may have the opportunity to participate in clinical research studies and clinical trials to better understand the relationship between bone marrow failure and MDS. […] Some patients may not experience symptoms, and MDS may be detected through a routine blood test that shows low counts for red blood cells, white blood cells, and/or platelets. […] In about 30% of patients, MDS develops into the more aggressive acute myeloid leukemia, which requires fast attention and treatment. […] The number of immature white blood cells, called blasts, is used to determine a patient’s MDS risk level: […] A patient has lower-risk MDS if fewer than 5% of their white cells are blasts. […] A patient has higher-risk MDS if 5-19% of their white cells are blasts. […] Your Dana-Farber physician will develop an individualized risk assessment, which considers traditional risk assessment factors, as well as your specific mutational profile.

• #36 How we diagnose Myelodysplastic syndromes

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11427428/

  The diagnostic process is based on various clinical and laboratory features with exclusion of other diseases. […] Once MDS is suspected, other causes of anemia or cytopenia are ruled out, and the patient is defined as having an unexplained anemia (or cytopenia), the next and definitive step in the diagnostic workup is a bone marrow (BM) evaluation, still the gold standard for the diagnosis of MDS. […] A full BM examination consists of both an aspirate and a biopsy. […] The main component to establish MDS diagnosis is morphology. […] In summary, BM examination, especially the dysplastic features and blast percentage are mandatory in establishing MDS diagnosis. […] Moreover, once diagnosed, these BM findings, and especially the blast percentage further assist in categorizing and predicting the prognosis of the patient, according to the various classifications.

• #37 MDS Diagnosis | The University of Kansas Cancer Center | Kansas City

  https://www.kucancercenter.org/cancer/cancer-types/myelodysplastic-syndromes/myelodysplastic-syndromes-diagnosis-screening

  Myelodysplastic syndromes (MDS) can be difficult to diagnose. Proper diagnosis is crucial and is most often made by a hematologist with advanced knowledge of myelodysplastic syndromes. […] To diagnose for myelodysplasia, your doctor takes 2 types of bone marrow samples: A bone marrow biopsy removes a small piece of bone along with the marrow inside the bone. A bone marrow aspirate draws out a sample of liquid from the bone marrow space. […] A hematologist will also look at your blood and bone marrow under a microscope to look for abnormal cell shapes and sizes additional indicators of MDS. Blood tests can also check the number of red blood cells, white blood cells and platelets in your blood, and whether the cells have changed in size or shape. […] To determine the type of MDS cancer, your doctor looks at several factors: Blood cell counts, how many blood cells look abnormal in their earliest forming stages within the bone marrow (also known as dysplasia), whether there’s a lower number of mature blood cells than normal (cytopenia), how many early red blood cells have an iron deposit ring around the nucleus (these are called ring sideroblasts), the percentage of very early blood cells (known as blasts) that are present in the bone marrow, certain chromosome changes at the cellular level in the bone marrow, and the risk that MDS could turn into leukemia. […] Classifying myelodysplasia helps doctors give an accurate diagnosis to better plan for your MDS cancer treatment.

• #38 Myelodysplastic Syndromes | Choose the Right Test

  https://arupconsult.com/content/myelodysplastic-syndromes

  Myelodysplastic syndromes (MDSs) are heterogeneous blood cancers characterized by ineffective hematopoiesis, cytopenia(s), and dysplasia(s). MDSs may progress to acute myeloid leukemia (AML). MDSs may also be associated with inherited genetic abnormalities or other hematologic conditions. Cytogenetic and molecular studies play a key role in the evaluation of patients with MDSs; results are used in diagnosis and classification, prognosis, medical management, and monitoring. […] The minimal diagnostic criteria for a myelodysplastic syndromes (MDSs) vary by organization. Both the International Consensus Classification (ICC) and World Health Organization (WHO) offer diagnostic and classification criteria that consider cytopenias, dysplasias, cytogenetic findings, and the exclusion of other disorders.

• #39 How we diagnose Myelodysplastic syndromes

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11427428/

  Cytogenetics is performed with a combination of G-banding and FISH techniques. […] While it may not be required to establish MDS diagnosis, no diagnostic workup is complete without performing it. […] In summary, one cannot underestimate the role of genetics in diagnosis, as well as in the pathogenesis and prognosis, but in 2024 we are still in the beginning of this era, and the genetic profile, although routinely performed in many parts of the world, is still not a mandatory tool in the diagnostic workup. […] To make the diagnosis of MDS, some tests are mandatory, especially BM examination (aspirate and/or biopsy) identifying dysplasia in one or more and enumeration of blasts, as well as exclusion of other reasons for anemia (or cytopenia).

• #40 What is Myelodysplastic Syndrome – MDS Disease Symptoms & Types | Max Hospital

  https://www.maxhealthcare.in/blogs/what-is-myelodysplastic-syndrome-mds

  Myelodysplastic syndrome (MDS) is a condition characterised by abnormal development and functioning of blood-forming cells (blood stem cells). […] The diagnosis of myelodysplastic syndrome involves a combination of clinical assessments, laboratory tests, and bone marrow examinations. […] A thorough medical history is obtained, including information about symptoms, past medical treatments (especially chemotherapy or radiation therapy), exposure to toxins, and family history. […] Complete blood count (CBC) is performed to evaluate the number and types of blood cells present. […] A bone marrow aspiration and biopsy are crucial for confirming the diagnosis of MDS. […] Chromosomal analysis (karyotyping) is performed on the bone marrow cells to identify any chromosomal abnormalities, such as deletions or translocations.

• #41

  https://haematologica.org/article/view/haematol.2023.284937

  Cytogenetic studies are performed with a combination of G-banding and fluorescence in situ hybridization techniques. […] While cytogenetic studies may not be required to establish a diagnosis of MDS, no diagnostic workup is complete without performing them. […] In summary, one cannot underestimate the role of genetics in diagnosis, as well as in pathogenesis and prognosis, but in 2024 we are still at the beginning of this era, and the genetic profile, although routinely determined in many parts of the world, is still not a mandatory tool in the diagnostic workup. […] It is very likely that in the near future, non-invasive techniques, such as diagnostic modeling, digital computational analysis and PB genetics, individually or in combination, will become part of general practice in the diagnosis of MDS.

• #42 Diagnosis and Classification of Myelodysplastic Syndrome | IntechOpen

  https://www.intechopen.com/chapters/64871

  The diagnosis of MDS requires a careful light microscopic examination of optimally stained peripheral blood and bone marrow smear and trephine biopsy sections with presence of 1% blast in peripheral blood, with 5% BM blasts and uni- or multilineage dysplasia is defined as unclassifiable MDS. […] The cytogenetic study of bone marrow aspirate has a major role in determining clonality in patients with MDS. Karyotyping should be done in all patients, at least 25 metaphases, whenever possible, and described according to International System recommendations. […] The presence monosomy 5, 7, or 13; 5q, 7q and 13q deletions; i(17p) and t(17p); 11q deletion; 9q or 12p deletion or t(12p), idic (X)(q13) allows for the diagnosis of MDS even in the absence of dysplastic changes. […] The last edition of WHO classification guidelines identify 6 types of MDS: MDS with single lineage dysplasia (MDS-SLD); MDS with ring sideroblasts (MDS-RS); MDS with multilineage dysplasia; MDS with excess blasts (MDS-EB); MDS with isolated del(5q); and MDS unclassifiable (MDS-U).

• #43 Myelodysplastic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK534126/

  Oncologists use the IPSS or R-IPSS scoring system to help guide the course of treatment. […] Treatment options include supportive measures, low-intensity treatment with systemic agents, or high-intensity treatment such as allogeneic stem cell transplant. […] The prognosis of patients with MDS varies widely depending upon several characteristics, including cytogenetics and severity of cytopenias. […] The IPSS and revised IPSS are risk stratification systems clinicians use to guide treatment and the potential clinical course.

• #44 What is Myelodysplastic Syndrome – MDS Disease Symptoms & Types | Max Hospital

  https://www.maxhealthcare.in/blogs/what-is-myelodysplastic-syndrome-mds

  Molecular tests may be conducted to identify specific genetic mutations associated with MDS, such as mutations in genes like TP53, SF3B1, or TET2. […] Once the diagnostic process is complete, the healthcare team can determine the specific subtype of MDS, assess the severity of the condition, and develop an appropriate treatment plan.

• #45 How We Diagnose Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/diagnosis

  Next-generation sequencing: Our patients have access to our Rapid Heme Panel — a next-generation sequencing test to identify mutations or DNA alterations in 95 genes that are frequently mutated in blood cancers. […] All newly-diagnosed MDS patients are offered a referral to our genetics program to be evaluated for any inherited mutations that may have contributed to the development of MDS. […] These tests provide valuable information about your disease and how likely it is to progress to AML. […] We routinely evaluate specimens sent to us from outside centers. […] Reasons to consider a consultation or second opinion include: […] To confirm your diagnosis. […] To determine the optimal therapy and timing of treatment. […] If you are a physician and have a patient with diagnosed or suspected MDS, we look forward to working with you.

• #46 How We Diagnose Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/diagnosis

  Next-generation sequencing: Our patients have access to our Rapid Heme Panel — a next-generation sequencing test to identify mutations or DNA alterations in 95 genes that are frequently mutated in blood cancers. […] All newly-diagnosed MDS patients are offered a referral to our genetics program to be evaluated for any inherited mutations that may have contributed to the development of MDS. […] These tests provide valuable information about your disease and how likely it is to progress to AML. […] We routinely evaluate specimens sent to us from outside centers. […] Reasons to consider a consultation or second opinion include: […] To confirm your diagnosis. […] To determine the optimal therapy and timing of treatment. […] If you are a physician and have a patient with diagnosed or suspected MDS, we look forward to working with you.

• #47 Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes

  We provide comprehensive services to patients with these cancers, including: […] A highly specialized program focusing on MDS diagnostics, treatment, and research. […] Access to the latest diagnostics, such as molecular and genomic profiling, including the Rapid Heme Panel, which was developed by our scientists to rapidly detect key mutations that are important for developing timely treatment plans.

• #48 How We Diagnose Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/diagnosis

  Next-generation sequencing: Our patients have access to our Rapid Heme Panel — a next-generation sequencing test to identify mutations or DNA alterations in 95 genes that are frequently mutated in blood cancers. […] All newly-diagnosed MDS patients are offered a referral to our genetics program to be evaluated for any inherited mutations that may have contributed to the development of MDS. […] These tests provide valuable information about your disease and how likely it is to progress to AML. […] We routinely evaluate specimens sent to us from outside centers. […] Reasons to consider a consultation or second opinion include: […] To confirm your diagnosis. […] To determine the optimal therapy and timing of treatment. […] If you are a physician and have a patient with diagnosed or suspected MDS, we look forward to working with you.

• #49

  https://haematologica.org/article/view/haematol.2023.284937

  Cytogenetic studies are performed with a combination of G-banding and fluorescence in situ hybridization techniques. […] While cytogenetic studies may not be required to establish a diagnosis of MDS, no diagnostic workup is complete without performing them. […] In summary, one cannot underestimate the role of genetics in diagnosis, as well as in pathogenesis and prognosis, but in 2024 we are still at the beginning of this era, and the genetic profile, although routinely determined in many parts of the world, is still not a mandatory tool in the diagnostic workup. […] It is very likely that in the near future, non-invasive techniques, such as diagnostic modeling, digital computational analysis and PB genetics, individually or in combination, will become part of general practice in the diagnosis of MDS.

• #50 MDS Diagnosis | The University of Kansas Cancer Center | Kansas City

  https://www.kucancercenter.org/cancer/cancer-types/myelodysplastic-syndromes/myelodysplastic-syndromes-diagnosis-screening

  Myelodysplastic syndromes (MDS) can be difficult to diagnose. Proper diagnosis is crucial and is most often made by a hematologist with advanced knowledge of myelodysplastic syndromes. […] To diagnose for myelodysplasia, your doctor takes 2 types of bone marrow samples: A bone marrow biopsy removes a small piece of bone along with the marrow inside the bone. A bone marrow aspirate draws out a sample of liquid from the bone marrow space. […] A hematologist will also look at your blood and bone marrow under a microscope to look for abnormal cell shapes and sizes additional indicators of MDS. Blood tests can also check the number of red blood cells, white blood cells and platelets in your blood, and whether the cells have changed in size or shape. […] To determine the type of MDS cancer, your doctor looks at several factors: Blood cell counts, how many blood cells look abnormal in their earliest forming stages within the bone marrow (also known as dysplasia), whether there’s a lower number of mature blood cells than normal (cytopenia), how many early red blood cells have an iron deposit ring around the nucleus (these are called ring sideroblasts), the percentage of very early blood cells (known as blasts) that are present in the bone marrow, certain chromosome changes at the cellular level in the bone marrow, and the risk that MDS could turn into leukemia. […] Classifying myelodysplasia helps doctors give an accurate diagnosis to better plan for your MDS cancer treatment.

• #51 Diagnosis and Classification of Myelodysplastic Syndrome | IntechOpen

  https://www.intechopen.com/chapters/64871

  The diagnosis of MDS requires a careful light microscopic examination of optimally stained peripheral blood and bone marrow smear and trephine biopsy sections with presence of 1% blast in peripheral blood, with 5% BM blasts and uni- or multilineage dysplasia is defined as unclassifiable MDS. […] The cytogenetic study of bone marrow aspirate has a major role in determining clonality in patients with MDS. Karyotyping should be done in all patients, at least 25 metaphases, whenever possible, and described according to International System recommendations. […] The presence monosomy 5, 7, or 13; 5q, 7q and 13q deletions; i(17p) and t(17p); 11q deletion; 9q or 12p deletion or t(12p), idic (X)(q13) allows for the diagnosis of MDS even in the absence of dysplastic changes. […] The last edition of WHO classification guidelines identify 6 types of MDS: MDS with single lineage dysplasia (MDS-SLD); MDS with ring sideroblasts (MDS-RS); MDS with multilineage dysplasia; MDS with excess blasts (MDS-EB); MDS with isolated del(5q); and MDS unclassifiable (MDS-U).

• #52 Myelodysplastic Syndrome (MDS) Guidelines: Guidelines Summary, Diagnosis, Prognostic Scoring Systems

  https://emedicine.medscape.com/article/207347-guidelines

  The NCCN utilizes the WHO classification system for diagnosis and distinguishes subtypes on the basis of blood and bone marrow findings. MDS with single-lineage dysplasia (MDS-SLD) criteria are as follows: Blood: single cytopenia or bicytopenia, Bone marrow: dysplasia in 10% of one cell line, 5% blasts. MDS with ring sideroblasts (MDS-RS) criteria are as follows: Blood: anemia, no blasts, Bone marrow: 15% of erythroid precursors with ring sideroblasts, or 5% blasts ring sideroblasts if SF3B1 mutation is present. MDS with multilineage dysplasia (MDS-MLD) criteria are as follows: Blood: cytopenia(s), 1 109/L monocytes, Bone marrow: dysplasia in 10% of cells in 2 hematopoietic lineages; 15% ring sideroblasts (or 5% ring sideroblasts if SF3B1 mutation present), 5% blasts. MDS with excess blasts-1 (MDS-EB-1) criteria are as follows: Blood: cytopenia(s) 2-4% blasts, 1 109/L monocytes, Bone marrow: unilineage or multilineage dysplasia, no Auer rods, 5-9% blasts. MDS with excess blasts-2 (MDS-EB-2) criteria are as follows: Blood: cytopenia(s), 5-19% blasts, 1 109/L monocytes, Bone marrow: unilineage or multilineage dysplasia, Auer rods, 10-19% blasts. Myelodysplastic syndrome unclassified (MDS-U) criteria are as follows: Blood: cytopenias, 1% blasts on at least 2 occasions, Bone marrow: unilineage dysplasia or no dysplasia but characteristic MDS cytogenetics, 5% blasts. Myelodysplastic syndrome associated with isolated del(5q) criteria are as follows: Blood: anemia, platelet levels normal or increased, Bone marrow: unilineage erythroid dysplasia, isolated del(5q), 5% blasts one other abnormality except -7/del(7q).

• #53 Myelodysplastic Syndrome (MDS) Guidelines: Guidelines Summary, Diagnosis, Prognostic Scoring Systems

  https://emedicine.medscape.com/article/207347-guidelines

  The NCCN utilizes the WHO classification system for diagnosis and distinguishes subtypes on the basis of blood and bone marrow findings. MDS with single-lineage dysplasia (MDS-SLD) criteria are as follows: Blood: single cytopenia or bicytopenia, Bone marrow: dysplasia in 10% of one cell line, 5% blasts. MDS with ring sideroblasts (MDS-RS) criteria are as follows: Blood: anemia, no blasts, Bone marrow: 15% of erythroid precursors with ring sideroblasts, or 5% blasts ring sideroblasts if SF3B1 mutation is present. MDS with multilineage dysplasia (MDS-MLD) criteria are as follows: Blood: cytopenia(s), 1 109/L monocytes, Bone marrow: dysplasia in 10% of cells in 2 hematopoietic lineages; 15% ring sideroblasts (or 5% ring sideroblasts if SF3B1 mutation present), 5% blasts. MDS with excess blasts-1 (MDS-EB-1) criteria are as follows: Blood: cytopenia(s) 2-4% blasts, 1 109/L monocytes, Bone marrow: unilineage or multilineage dysplasia, no Auer rods, 5-9% blasts. MDS with excess blasts-2 (MDS-EB-2) criteria are as follows: Blood: cytopenia(s), 5-19% blasts, 1 109/L monocytes, Bone marrow: unilineage or multilineage dysplasia, Auer rods, 10-19% blasts. Myelodysplastic syndrome unclassified (MDS-U) criteria are as follows: Blood: cytopenias, 1% blasts on at least 2 occasions, Bone marrow: unilineage dysplasia or no dysplasia but characteristic MDS cytogenetics, 5% blasts. Myelodysplastic syndrome associated with isolated del(5q) criteria are as follows: Blood: anemia, platelet levels normal or increased, Bone marrow: unilineage erythroid dysplasia, isolated del(5q), 5% blasts one other abnormality except -7/del(7q).

• #54 Myelodysplastic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK534126/

  Oncologists use the IPSS or R-IPSS scoring system to help guide the course of treatment. […] Treatment options include supportive measures, low-intensity treatment with systemic agents, or high-intensity treatment such as allogeneic stem cell transplant. […] The prognosis of patients with MDS varies widely depending upon several characteristics, including cytogenetics and severity of cytopenias. […] The IPSS and revised IPSS are risk stratification systems clinicians use to guide treatment and the potential clinical course.

• #55 Myelodysplastic Syndrome (MDS) Symptoms & Diagnosis | Herbert Irving Comprehensive Cancer Center (HICCC) – New York

  https://www.cancer.columbia.edu/cancer-types-care/types/myelodysplastic-syndrome/about-myelodysplastic-syndrome

  Doctors generally use the revised International Prognostic Scoring System (IPSS-R) to determine your prognosis and risk for developing acute leukemia. It also helps them know when to start treatment and choose the most appropriate treatment. IPSS takes into account: The percentage of blasts (immature blood cells) in the bone marrow, Complete blood count results, Certain genetic abnormalities.

• #56 Myelodysplastic Syndrome (MDS) Symptoms & Diagnosis | Herbert Irving Comprehensive Cancer Center (HICCC) – New York

  https://www.cancer.columbia.edu/cancer-types-care/types/myelodysplastic-syndrome/about-myelodysplastic-syndrome

  Doctors generally use the revised International Prognostic Scoring System (IPSS-R) to determine your prognosis and risk for developing acute leukemia. It also helps them know when to start treatment and choose the most appropriate treatment. IPSS takes into account: The percentage of blasts (immature blood cells) in the bone marrow, Complete blood count results, Certain genetic abnormalities.

• #57 Myelodysplastic neoplasms (MDS) – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myelodysplastic-syndromes/

  The risk of your MDS progressing into acute myeloid leukaemia (AML) and your life expectancy can be calculated by your treatment team. The score is calculated using the International Prognostic Scoring System – Molecular (IPSS-M) risk calculator. […] Your haematologist will recommend treatment based on: the type of MDS you have, your age, your general health, your prognosis, your wishes.

• #58 Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes

  Patients may have the opportunity to participate in clinical research studies and clinical trials to better understand the relationship between bone marrow failure and MDS. […] Some patients may not experience symptoms, and MDS may be detected through a routine blood test that shows low counts for red blood cells, white blood cells, and/or platelets. […] In about 30% of patients, MDS develops into the more aggressive acute myeloid leukemia, which requires fast attention and treatment. […] The number of immature white blood cells, called blasts, is used to determine a patient’s MDS risk level: […] A patient has lower-risk MDS if fewer than 5% of their white cells are blasts. […] A patient has higher-risk MDS if 5-19% of their white cells are blasts. […] Your Dana-Farber physician will develop an individualized risk assessment, which considers traditional risk assessment factors, as well as your specific mutational profile.

• #59 Myelodysplasia or myelodysplastic syndrome (MDS) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/blood-cancer/myelodysplasia-mds

  Myelodysplasia is also called myelodysplastic syndrome (MDS). MDS is a type of blood cancer that affects the bone marrow. […] If your doctor thinks you may have MDS, they will refer to you to the hospital to see a specialist blood doctor called a haematologist. […] Your haematologist will decide whether you need further tests. This can include more blood tests and a bone marrow biopsy. […] Doctors often use a system called the revised International Prognostic Scoring System (IPSS-R). It divides MDS into 5 risk groups: […] Before treatment, a team of health professionals work together to plan the treatment they feel is best for you. This team is called a multi-disciplinary team (MDT). […] The MDT look at your: […] Your doctor will talk with you about treatment options. Treatments may be used to help with symptoms or reduce the risk of complications of MDS. This is called supportive treatment.

• #60 Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes

  Patients may have the opportunity to participate in clinical research studies and clinical trials to better understand the relationship between bone marrow failure and MDS. […] Some patients may not experience symptoms, and MDS may be detected through a routine blood test that shows low counts for red blood cells, white blood cells, and/or platelets. […] In about 30% of patients, MDS develops into the more aggressive acute myeloid leukemia, which requires fast attention and treatment. […] The number of immature white blood cells, called blasts, is used to determine a patient’s MDS risk level: […] A patient has lower-risk MDS if fewer than 5% of their white cells are blasts. […] A patient has higher-risk MDS if 5-19% of their white cells are blasts. […] Your Dana-Farber physician will develop an individualized risk assessment, which considers traditional risk assessment factors, as well as your specific mutational profile.

• #61 Myelodysplastic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK534126/

  Oncologists use the IPSS or R-IPSS scoring system to help guide the course of treatment. […] Treatment options include supportive measures, low-intensity treatment with systemic agents, or high-intensity treatment such as allogeneic stem cell transplant. […] The prognosis of patients with MDS varies widely depending upon several characteristics, including cytogenetics and severity of cytopenias. […] The IPSS and revised IPSS are risk stratification systems clinicians use to guide treatment and the potential clinical course.

• #62 Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds

  MDS must be distinguished from other conditions that are associated with dysplasia, cytopenias, and/or clonality; some conditions in the differential diagnosis exhibit more than one of these features. […] The differential diagnosis of MDS must be considered carefully, as incorrect diagnoses are common.

• #63 Myelodysplastic Syndrome (MDS) Differential Diagnoses

  https://emedicine.medscape.com/article/207347-differential

  Myelodysplastic syndrome (MDS) is typically diagnosed by finding some combination of dysplastic cell morphology, increased marrow blasts, and a karyotypic abnormality. […] Other causes of cytopenias must be excluded. […] Common etiologies of cytopenias or morphologic abnormalities that may mimic MDS include the following: Medication (eg, methotrexate), Deficiencies of cobalamin, folate, or copper, Alcohol abuse, HIV infection, Immune-mediated cytopenias (eg, aplastic anemia, large granular lymphocyte leukemia), Congenital syndromes (eg, Fanconi anemia, X-linked sideroblastic anemia), Idiopathic cytopenia of undetermined significance (ICUS), Idiopathic dysplasia of undetermined significance (IDUS).

• #64 Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS) – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds

  MDS must be distinguished from other conditions that are associated with dysplasia, cytopenias, and/or clonality; some conditions in the differential diagnosis exhibit more than one of these features. […] The differential diagnosis of MDS must be considered carefully, as incorrect diagnoses are common.

• #65 https://www.lls.org/myelodysplastic-syndromes/diagnosis

  https://www.lls.org/myelodysplastic-syndromes/diagnosis

  An accurate diagnosis is one of the most important aspects of a persons care. Obtaining a precise diagnosis will help the doctor […] Since MDS can be a difficult disease to diagnose, you may want to get a second medical opinion by an experienced hematopathologist before you begin treatment. […] The diagnosis of MDS is based on: […] A doctor will order a complete blood count (CBC) with differential to measure the number of red cells, white cells and platelets in your blood. These measurements indicate the degree to which the MDS cells in the marrow are affecting normal blood cell development. […] Reticulocytes are precursor (immature) cells that develop into mature red blood cells. The reticulocyte count measures the number of reticulocytes in the circulating blood. It can show how quickly these cells are being made and released by the bone marrow and whether the bone marrow is functioning properly.

• #66 How We Diagnose Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/diagnosis

  Next-generation sequencing: Our patients have access to our Rapid Heme Panel — a next-generation sequencing test to identify mutations or DNA alterations in 95 genes that are frequently mutated in blood cancers. […] All newly-diagnosed MDS patients are offered a referral to our genetics program to be evaluated for any inherited mutations that may have contributed to the development of MDS. […] These tests provide valuable information about your disease and how likely it is to progress to AML. […] We routinely evaluate specimens sent to us from outside centers. […] Reasons to consider a consultation or second opinion include: […] To confirm your diagnosis. […] To determine the optimal therapy and timing of treatment. […] If you are a physician and have a patient with diagnosed or suspected MDS, we look forward to working with you.

• #67 How We Diagnose Myelodysplastic Syndromes (MDS) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/diagnosis

  Next-generation sequencing: Our patients have access to our Rapid Heme Panel — a next-generation sequencing test to identify mutations or DNA alterations in 95 genes that are frequently mutated in blood cancers. […] All newly-diagnosed MDS patients are offered a referral to our genetics program to be evaluated for any inherited mutations that may have contributed to the development of MDS. […] These tests provide valuable information about your disease and how likely it is to progress to AML. […] We routinely evaluate specimens sent to us from outside centers. […] Reasons to consider a consultation or second opinion include: […] To confirm your diagnosis. […] To determine the optimal therapy and timing of treatment. […] If you are a physician and have a patient with diagnosed or suspected MDS, we look forward to working with you.

• #68 How we diagnose Myelodysplastic syndromes

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11427428/

  Cytogenetics is performed with a combination of G-banding and FISH techniques. […] While it may not be required to establish MDS diagnosis, no diagnostic workup is complete without performing it. […] In summary, one cannot underestimate the role of genetics in diagnosis, as well as in the pathogenesis and prognosis, but in 2024 we are still in the beginning of this era, and the genetic profile, although routinely performed in many parts of the world, is still not a mandatory tool in the diagnostic workup. […] To make the diagnosis of MDS, some tests are mandatory, especially BM examination (aspirate and/or biopsy) identifying dysplasia in one or more and enumeration of blasts, as well as exclusion of other reasons for anemia (or cytopenia).

• #69

  https://haematologica.org/article/view/haematol.2023.284937

  Cytogenetic studies are performed with a combination of G-banding and fluorescence in situ hybridization techniques. […] While cytogenetic studies may not be required to establish a diagnosis of MDS, no diagnostic workup is complete without performing them. […] In summary, one cannot underestimate the role of genetics in diagnosis, as well as in pathogenesis and prognosis, but in 2024 we are still at the beginning of this era, and the genetic profile, although routinely determined in many parts of the world, is still not a mandatory tool in the diagnostic workup. […] It is very likely that in the near future, non-invasive techniques, such as diagnostic modeling, digital computational analysis and PB genetics, individually or in combination, will become part of general practice in the diagnosis of MDS.

• #70 How we diagnose Myelodysplastic syndromes

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11427428/

  The Myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by ineffective hematopoiesis that results in dysplasia in hematopoietic cells and peripheral cytopenias, especially anemia, and a propensity to leukemic transformation. […] The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings, but the gold standard for MDS diagnosis is still BM examination with the presence of uni-or multi-lineage dysplasia and increased blast percentage, together with exclusion of other reasons. […] Cytogenetics is also an essential part of the diagnostic and prognostic processes. […] Unfortunately, since we are dealing with a heterogenous group of disorders, in contrast with many other diseases, there is no single specific diagnostic test or definitive diagnostic criteria for MDS.

• #71

  https://haematologica.org/article/view/haematol.2023.284937

  The myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by BM dysplasia, macrocytic anemia or cytopenia with a tendency for leukemic transformation. […] The gold standard for the diagnosis of MDS is still BM examination with the presence of uni-or multi-lineage dysplasia and blast percentage, together with exclusion of other reasons. […] Cytogenetics is also a part of the diagnostic process. […] This review summarizes the current steps in the diagnostic approach for a patient suspected of having MDS. […] The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings. […] MDS is suspected when there are appropriate clinical and laboratory findings, especially in the elderly.

• #72 Myelodysplastic syndromes – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/diagnosis-treatment/drc-20366980

  A needle suctioning out liquid bone marrow from hipbone Bone marrow exam […] A physical exam, medical history and tests might be used if your doctor suspects that you have a myelodysplastic syndrome. […] Blood and bone marrow samples are sent for laboratory analysis. Specialized tests can determine the specific characteristics of your cells that will be helpful for determining the type of myelodysplastic syndrome you have, your prognosis and your treatment options. […] A bone marrow transplant, also known as a stem cell transplant, is the only treatment option that offers the potential of a cure for myelodysplastic syndromes. […] During a bone marrow transplant, high doses of chemotherapy drugs are used to clear out the defective blood cells from your bone marrow. Then the abnormal bone marrow stem cells are replaced with healthy, donated cells (allogeneic transplant). […] If your doctor suspects that you have a myelodysplastic syndrome, you might be referred to a doctor who specializes in blood disorders (hematologist).

• #73 Myelodysplastic Syndrome (MDS): Symptoms, Diagnosis & Treatment

  https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia

  Treatment for myelodysplastic syndrome may include supportive care and treatment to get rid of unhealthy blood cells. […] The only cure for MDS is a successful stem cell transplant. Unfortunately, not everyone can have this treatment. […] Myelodysplastic syndrome is a serious health issue that can cause life-threatening conditions. Its also a complicated health issue that affects people in different ways. Your healthcare provider is your best source of information about your individual prognosis or expected outcome.

Zobacz więcej